Leprosy: From Diagnosis to Treatment

Daniel L. Knuth (Editor)

Series: Bacteriology Research Developments, Rare Disorders Research Progress
BISAC: MED022090

Clear

$82.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Leprosy: From Diagnosis to Treatment discusses the current public health challenges in leprosy control face, exploring opportunities that may potentially accelerate progress towards the elimination of leprosy.

Leprosy is the least contagious of infectious diseases; it is caused by M. leprae and M. lepromatosis and mainly affects the skin and peripheral nerves. In addition to existing interest due to the variation in the clinical characteristics of the disease between people, the immune response in this pathology will also differ.

In the course of the disease, leprosy patients can experience episodes of acute inflammatory reactions known as leprosy reactions. Leprosy reactions are complications that may occur before, during, or after treatment, and cause further neurological damages that can cause chronic disabilities. As such, the authors discuss the role of immune response in leprosy pathogenesis and leprosy reactions.

The treatment of leprosy is always based on the final clinical and laboratory confirmation of the diagnosis. The diagnosed patient must be treated for 6 months in case of paucibacillary and 12 months in case of multibacillary. Further, precaution should be always taken to treat a confirmed disease, as many diseases mimic leprosy.

In closing, the authors highlight the current evidence about the association of vitamin D and VDR to leprosy disease progression. This knowledge will help in developing new strategies for the treatment and clinical management of leprosy patients.
(Imprint: Nova Medicine and Health)

Preface

Chapter 1. Public Health Challenges and Opportunities in Leprosy Control: from Theory to Implementation
(Sarah Galvani-Townsend, Pratha Sah and Abhishek Pandey, Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT, USA)

Chapter 2. Leprosy Immunology
(Mary Fafutis-Morris, PhD, and Jorge J. R. Padilla-Arellano, Departamento de Fisiología, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico, and others)

Chapter 3. Immunological Aspect of Leprosy
(Nyoman Suryawati, Dermatology and Venereology Department, Faculty of Medicine, Udayana University, Denpasar, Bali, Indonesia)

Chapter 4. Treatment of Leprosy: Current Practice and Updated WHO Guidelines
(T. Pugazhenthan, MD, V. Sajitha, Pharmacology,All India Institute Of Medical Sciences, Raipur, India, and others)

Chapter 5. Association of Vitamin D and the Vitamin D Receptor (VDR) in Leprosy Disease Progression: Implication of New Strategies for Treatment and Clinical Management
(Dibyakanti Mandal, PhD, Department of Biochemistry, PDM University, Haryana, India)

Index

You have not viewed any product yet.